Evidence map›Paper›PMID 41324571›Full record

ArticleThe Journal of general virology2025

Robust antibody and T cell responses tracked longitudinally in patients with long COVID.

Marina Metaxaki, Ranjana Ram, Marianne Perera, Mark Wills, Benjamin A Krishna, Nyarie Sithole

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of general virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marina MetaxakiCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge CB2 0AW, UK.
Ranjana RamCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge CB2 0AW, UK.
Marianne PereraPresent address: Department of Pathology, University of Cambridge, Cambridge CB2 0QQ, UK.
Mark WillsCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge CB2 0AW, UK.
Benjamin A KrishnaCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge CB2 0AW, UK.
Nyarie SitholeCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge CB2 0AW, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

After severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a minority of patients experience persistent or emerging symptoms, termed 'long coronavirus disease (COVID)' or post-acute sequelae of COVID-19. The molecular causes of long COVID remain unclear, but disrupted immune functions, such as inflammation and immune deficit, have been posited as factors. In this retrospective cohort study, we measured markers of immune function in a group of patients with long COVID up to 40 months post infection. As proxies for immune function, we measured serum antibody levels, antibody neutralizing capability and production of IFN gamma (IFN-

Indexed as

Antibodies, ViralCOVID-19SARS-CoV-2T-LymphocytesAdultAgedAntibodies, NeutralizingFemaleHumansInterferon-gammaInterleukin-2Longitudinal StudiesMaleMiddle AgedPost-Acute COVID-19 SyndromeRetrospective StudiesAntibodies, NeutralizingAntibodies, ViralInterferon-gammaInterleukin-2antibodylong COVIDlongitudinalT cell

Identifiers

PMID41324571
PMCPMC12668617

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.